The effect of dose rate and adriamycin on the tolerance of thoracic radiation in mice.
Radiation damage to the lung may be a predisposing factor in the development of interstitial pneumonitis in patients undergoing total body radiation and subsequent bone marrow transplantation in the treatment of leukemia. Adriamycin has been used in conjunction with bone marrow transplantation, and has also been shown to interact with radiation. This experiment was designed to study the effects of pre-administration of adriamycin on the radiation tolerance of the lung and esophagus. Since total body radiation is usually administered at low dose rates in order to spare the gastrointestinal tract preferentially as compared to the bone marrow, we investigated whether such a dose rate effect was present for the lung and if so, whether this pulmonary and esophageal dose rate effect would be ameliorated by pre-treatment with adriamycin. Mice were irradiated at 5 rad; 15 rad or 70 rad per minute to the upper body, 24 hours or 7 days after adriamycin. Oral esophageal death occurred within one month; thus deaths within 30 days were ascribed to this mechanism. In comparison, deaths because of pulmonary toxicity occurred later. Those between 30 and 160 days were ascribed to this mechanism. In the absence of adriamycin, a dose rate effect was found for the lung and confirmed for the upper gastrointestinal tract. The dose of radiation necessary to give pulmonary and gastrointestinal toxicity was markedly reduced when adriamycin was administered 24 hours before radiation. If seven days were allowed between adriamycin and radiation there was still an effect seen only at the high dose rate for the esophagus while for the lung at the high dose rate and for both systems at low dose rate no significant drug effects were noted. The dose rate effect is still seen after the drug, but it is reduced. These studies indicate that adriamycin given shortly before can significantly increase the oral esophageal and pulmonary toxicity of radiation and can practically abrogate the sparing effect of dose rate. This must be considered when clinically using total body radiation and adriamycin in preparation for bone marrow transplantation.
D000818:Animals; D016026:Bone Marrow Transplantation; D004307:Dose-Response Relationship, Radiation; D004317:Doxorubicin / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004947:Esophagus / Q000187:drug effects / Q000528:radiation effects; D007928:Lethal Dose 50; D007942:Leukemia, Experimental / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D008168:Lung / Q000187:drug effects / Q000528:radiation effects; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D011836:Radiation Tolerance; D011879:Radiotherapy Dosage; D014916:Whole-Body Irradiation
D004317:Doxorubicin